Oncology
OTHER
Review explores potential kidney cancer treatment target and challenges
Frontiers in Medicine
Published April 1, 2026
A recent review article looked at existing research on a cell communication system called the PI3K-AKT-mTOR pathway in kidney cancer, specifically renal cell carcinoma (RCC). The article summarized what other studies have found, rather than reporting new patient data. It explained that this pathway is frequently overactive in RCC tumors, and this overactivity is associated with the cancer growing and spreading, as well as with poorer patient outcomes.
The review discussed that drugs designed to block this pathway, called small-molecule inhibitors, have shown promise in laboratory studies and very early human trials. It also mentioned the idea of combining these drugs with other treatments, including some natural products, as a potential future strategy. However, the article did not report on any specific new clinical trial results, patient numbers, or safety data from these approaches.
It is important to understand that this is a review of existing literature, not a new clinical study. The potential treatments it discusses are still in the research phase. The article itself notes that turning these laboratory findings into reliable, effective treatments for patients faces significant clinical challenges. Readers should view this as a summary of ongoing scientific exploration into a complex cancer, not as a report on a ready-to-use new therapy.
View Original Abstract ↓
Renal cell carcinoma (RCC) is a type of solid tumor with one of the highest incidences among urinary system malignancies, and its incidence continues to increase worldwide. The PI3K-AKT-mTOR signaling pathway, as a central signaling hub that regulates biological processes such as cell survival, proliferation, metabolism, and metastasis, often exhibits abnormal and sustained activation during the pathological progression of RCC. Dysregulation of this pathway synergistically promotes tumor progression through multiple mechanisms, including enhancing the survival and clonal expansion of tumor cells, inducing angiogenesis, driving metabolic reprogramming of the tumor microenvironment, and mediating treatment resistance. These pathological changes are closely associated with poor patient prognosis. Given the central role of the PI3K-AKT-mTOR signaling pathway in the pathogenesis of RCC, it has become a key target for targeted therapeutic intervention. Although multiple small-molecule inhibitors targeting this pathway have demonstrated potential for inhibiting tumor growth in preclinical studies and early-phase clinical trials, their clinical application still faces numerous challenges. Against this backdrop, combination therapy strategies offer a new approach to overcome the limitations of single-agent therapy, not only enhancing treatment efficacy but also potentially reducing the risk of drug resistance. Notably, natural products and their derivatives, due to their low toxicity, ability to modulate multiple targets, and specific inhibitory effects on cancer stem cells, are regarded as promising sensitizers in combination therapy. This article systematically reviews the pathological features of RCC and current clinical treatment strategies, with a focus on exploring the molecular regulatory mechanisms of the PI3K-AKT-mTOR signaling pathway in tumor progression, while highlighting the latest research advances in small-molecule inhibitors targeting this pathway. Integrating preclinical mechanistic studies and relevant clinical trial data, the limitations of existing agents are analyzed, and potential optimization directions are proposed, aiming to provide theoretical support and practical references for the clinical translation of precision therapy for RCC and to promote the transformation of pathway-based combination therapy models into clinical applications.
